{
    "ticker": "EOLS",
    "name": "Evolus, Inc.",
    "description": "Evolus, Inc. is a performance beauty company focused on delivering innovative aesthetic products to the global market. Founded in 2012 and headquartered in Newport Beach, California, Evolus is dedicated to meeting the needs of consumers and healthcare providers through cutting-edge technology and unique formulations. The company's flagship product, Jeuveau, is a botulinum toxin injectable specifically designed for aesthetic use, targeting frown lines and helping to enhance facial appearance. Evolus is committed to promoting beauty from within and aims to make aesthetic treatments accessible and affordable for everyone. Through its commitment to research and development, Evolus continues to explore new product lines and expand its offerings in the aesthetic market. The company's mission is to redefine the aesthetic experience and empower individuals to feel confident and beautiful in their own skin. Evolus focuses on building strong relationships with healthcare professionals and ensuring customer satisfaction through exceptional service and support. As a publicly traded company on the NASDAQ, Evolus is positioned for growth in the evolving beauty sector, capitalizing on trends that favor non-invasive aesthetic procedures.",
    "industry": [
        "Pharmaceuticals",
        "Aesthetics"
    ],
    "headquarters": "Newport Beach, California, USA",
    "founded": "2012",
    "website": "https://www.evolus.com",
    "ceo": "David Moatazedi",
    "social_media": {
        "twitter": "https://twitter.com/evolus",
        "linkedin": "https://www.linkedin.com/company/evolus/",
        "instagram": "https://www.instagram.com/evolusinc/",
        "youtube": "https://www.youtube.com/channel/UCAOaX1G2R0cRyc-5y6Wf1cQ"
    },
    "investor_relations": "https://investor.evolus.com",
    "key_executives": [
        {
            "name": "David Moatazedi",
            "position": "CEO"
        },
        {
            "name": "Catherine D. Buroker",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Injectables",
            "products": [
                "Jeuveau"
            ]
        },
        {
            "category": "Skincare",
            "products": [
                "Upcoming product lines"
            ]
        }
    ],
    "seo": {
        "meta_title": "Evolus, Inc. | Innovative Aesthetic Solutions",
        "meta_description": "Explore Evolus, Inc., a leader in aesthetic products focused on delivering beauty solutions. Discover our flagship injectable Jeuveau and our commitment to innovation in the beauty industry.",
        "keywords": [
            "Evolus",
            "Aesthetic Products",
            "Injectables",
            "Jeuveau",
            "Beauty Industry",
            "Non-invasive Treatments"
        ]
    },
    "faq": [
        {
            "question": "What is Evolus known for?",
            "answer": "Evolus is known for its aesthetics products, particularly the injectable Jeuveau for treating frown lines."
        },
        {
            "question": "Who is the CEO of Evolus?",
            "answer": "David Moatazedi is the CEO of Evolus, Inc."
        },
        {
            "question": "Where is Evolus headquartered?",
            "answer": "Evolus is headquartered in Newport Beach, California, USA."
        },
        {
            "question": "What are Evolus's main products?",
            "answer": "Evolus's main product is Jeuveau, a botulinum toxin injectable for aesthetic use."
        },
        {
            "question": "When was Evolus founded?",
            "answer": "Evolus was founded in 2012."
        }
    ],
    "competitors": [
        "ALLERGAN",
        "PRTO",
        "HZO"
    ],
    "related_stocks": [
        "AMGN",
        "VRTX",
        "REGN",
        "BMY"
    ]
}